Your shopping cart is currently empty

FLT3D835Y/F691L-IN-1 (compd 8v) is an orally active inhibitor targeting the secondary mutations D835Y/F691L in the FLT3 tyrosine kinase domain, with IC50 values of 1.5 and 9.7 nM, respectively. This compound is applicable in research related to acute myeloid leukemia.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | FLT3D835Y/F691L-IN-1 (compd 8v) is an orally active inhibitor targeting the secondary mutations D835Y/F691L in the FLT3 tyrosine kinase domain, with IC50 values of 1.5 and 9.7 nM, respectively. This compound is applicable in research related to acute myeloid leukemia. |
| In vitro | FLT3D835Y/F691L-IN-1 (0.16-100 nM, 4 h) inhibits the phosphorylation of FLT3 and cell cycle-associated proteins CDK4/6 and Cyclin D3. It also suppresses the proliferation of transfected Ba/F3 cells with FLT3-ITD, FLT3-ITD-D835Y, FLT3-ITD-F691L, FLT3-ITD-D835Y-F691L mutations and the MV4-11 acute myeloid leukemia cell line, with IC50 values of 12.2, 10.5, 24.6, 16.9, and 6.8 nM, respectively. |
| In vivo | FLT3D835Y/F691L-IN-1, administered orally at a dosage of 30 mg/kg daily for 28 days, effectively reduces tumor volume in mice with Ba/F3-FLT3-ITD-D835Y xenografts. |
| Formula | C26H37N7O4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.